SynthesisInternational journal of molecular sciences2021
Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
Synthesis in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Review
- Integrated approaches to sensitizing melanoma to radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- Article
- Efficacy and safety of hypofractionated radiotherapy for melanoma brain metastases: a retrospective study.Frontiers in oncology · 2026Article
- Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial.Frontiers in oncology · 2026Article
- Patterns, causes, and clinical impact of treatment interruption on early outcomes in patients receiving radiotherapy for lung cancer: a retrospective study.Frontiers in oncology · 2026Article
- Impact of differences in computed tomography value-electron density/physical density conversion tables on calculate dose in low-density areas.Physical and engineering sciences in medicine · 2025Article
- Research hotspots and trends in lung cancer immunotherapy are revealed by a bibliometric study spanning the years 2004 to 2024.Human vaccines & immunotherapeutics · 2025Article
- Combination of immune checkpoint inhibitors and radiotherapy for bone metastases induces an abscopal effect and improves outcomes in non-small cell lung cancer.Oncology letters · 2025Article
- Research Progress of SBRT Combined With Immunotherapy in Locally Advanced Head and Neck Cancer.American journal of clinical oncology · 2025Review
- Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical Strategies.International journal of molecular sciences · 2025Review
- mJournal for immunotherapy of cancer · 2025Review
- Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma.Clinical and translational radiation oncology · 2024Article
- The optimal stereotactic body radiotherapy dose with immunotherapy for pulmonary oligometastases: a retrospective cohort study.Journal of thoracic disease · 2024Article
- The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).Oncology reports · 2024Review
- Article
- External Beam Radiotherapy in Advanced Pheochromocytoma and Paraganglioma: An Observation of a Rare Abscopal Effect.JCEM case reports · 2023Article
- Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy.Frontiers in immunology · 2023Review
- Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer.Frontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.